公开(公告)号：US20250043306A1

公开(公告)日：2025-02-06

申请号：US18364935

申请日：2023-08-03

Applicant: ABS Global, Inc.

Inventor： Andrew Mark Cigan ,  Brian Timothy Burger

IPC: C12N15/85 ,  A01K67/027 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90

Abstract: Disclosed are gene edited ungulate animals and methods of editing genes that control various ungulate traits. Such methods include CRISPR, zinc fingers, or TALENS. Exemplary traits for editing include polled, sterility or fertility, milk production, growth (which increases meat production), fat production, conception rates, stillborn rates, calving ease, or content of produced milk such as the amount of protein or the amount of fat. Other traits include backfat thickness, intramuscular fat, ultrasound loin muscle area, loin muscle area and intramuscular fat content, chest circumference, withers height, body length, hip height, rump length, and heart girth. Other exemplary native traits include, but are not limited to, high altitude adaptation and response to hypoxia, cold acclimation, body size and stature, resistance to disease and bacterial infection, reproduction, milk yield and components, and feed efficiency.

公开(公告)号：US12213464B2

公开(公告)日：2025-02-04

申请号：US16757505

申请日：2018-10-19

Applicant: The Governors of the University of Alberta

Inventor： Graham Plastow ,  Mohammed Abo-Ismail

IPC: C12Q1/68 ,  A01K67/027 ,  C12P19/34 ,  C12Q1/6876

Abstract: Methods of identifying cattle having increased feed efficiency using a small panel of single nucleotide polymorphisms is provided. The method provides for using a thousand or less of such SNPs and includes using a panel of 250 or fewer SNPs. The method if useful with various cattle breeds including crossbred cattle. Provided are SNPs that are useful as markers with various traits associated with feed efficiency in cattle. Kits and methods of use are provided.

公开(公告)号：US12180504B2

公开(公告)日：2024-12-31

申请号：US17348619

申请日：2021-06-15

Applicant: The Regents of the University of California ,  University of Vienna ,  Emmanuelle Charpentier

Inventor： Jennifer A. Doudna ,  Martin Jinek ,  Krzysztof Chylinski ,  Emmanuelle Charpentier

IPC: C12N15/90 ,  A01H6/46 ,  A01K67/027 ,  A61K38/46 ,  A61K48/00 ,  C12N9/22 ,  C12N15/10 ,  C12N15/11 ,  C12N15/113 ,  C12N15/63 ,  C12N15/70 ,  C12N15/74 ,  C12Q1/686 ,  H01L21/02 ,  H01L33/00

Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.

公开(公告)号：US20240417756A1

公开(公告)日：2024-12-19

申请号：US18751730

申请日：2024-06-24

Applicant: The Regents of the University of California ,  University of Vienna ,  Emmanuelle Charpentier

Inventor： Jennifer A. Doudna ,  Martin Jinek ,  Krzysztof Chylinski ,  Emmanuelle Charpentier

IPC: C12N15/90 ,  A01H6/46 ,  A01K67/027 ,  A61K38/46 ,  A61K48/00 ,  C12N9/22 ,  C12N15/10 ,  C12N15/11 ,  C12N15/113 ,  C12N15/63 ,  C12N15/70 ,  C12N15/74 ,  C12Q1/686 ,  H01L21/02 ,  H01L33/00

Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.

公开(公告)号：US12156517B1

公开(公告)日：2024-12-03

申请号：US17680379

申请日：2022-02-25

Applicant: The Jackson Laboratory

Inventor： Michael V. Wiles ,  Derry C. Roopenian ,  Greg Christianson ,  Benjamin E. Low

IPC: A01K67/027 ,  A01K67/0278 ,  C07K14/735 ,  C07K16/00 ,  C07K16/28 ,  C07K16/46

Abstract: The present disclosure provides improved humanized IgG1 FCRN mouse models for use, for example, in estimating serum half-life of therapeutic proteins such as monoclonal antibodies.

公开(公告)号：US20240269160A1

公开(公告)日：2024-08-15

申请号：US18418193

申请日：2024-01-19

Applicant: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Inventor： Chen CHEN ,  Huaping LI ,  Daowen WANG ,  Beibei DAI

IPC: A61K31/7068 ,  A01K67/027 ,  A61P43/00 ,  C12N15/113 ,  C12N15/86

CPC classification number: A61K31/7068 ,  A01K67/027 ,  A61P43/00 ,  C12N15/113 ,  C12N15/86 ,  A01K2207/05 ,  A01K2267/0306 ,  C12N2310/122 ,  C12N2750/14143

Abstract: The present invention of use of citicoline in regulating respiratory chain function related protein level and preparing drug for preventing and treating respiratory chain dysfunction belongs to the field of drug. The present invention provides use of citicoline in regulating respiratory chain function related protein level, and also provides use of citicoline in preparing drug for preventing and treating respiratory chain dysfunction. The present invention also provides a shRNA causing respiratory chain dysfunction, its reverse complementary sequence is shown as SEQ ID NO. 2. The present invention also provides use of shRNA in preparing a respiratory chain dysfunction animal model, as well as its preparation method. It's confirmed by experiments that citicoline can effectively reverse molecular level symptoms of respiratory chain dysfunction and can be used as a drug for treating respiratory chain dysfunction.

公开(公告)号：US20240138383A1

公开(公告)日：2024-05-02

申请号：US18316688

申请日：2023-05-12

Applicant: GloFish LLC

Inventor： Alan Blake ,  Richard Crockett ,  Jeffrey Essner ,  Perry Hackett ,  Aidas Nasevicius

IPC: A01K67/0275 ,  A01K67/027 ,  C07K14/435 ,  C12N15/85 ,  G06Q99/00

CPC classification number: A01K67/0275 ,  A01K67/027 ,  C07K14/43595 ,  C12N15/8509 ,  G06Q99/00 ,  A01K2217/05 ,  A01K2217/052 ,  A01K2217/206 ,  A01K2227/40 ,  A01K2267/0393 ,  C12N2830/008

Abstract: The present invention relates to the method and use of reef coral fluorescent proteins in making transgenic red, green and yellow fluorescent zebrafish. Preferably, such fluorescent zebrafish are fertile and used to establish a population of transgenic zebrafish and to provide to the ornamental fish industry for the purpose of marketing. Thus, new varieties of ornamental fish of different fluorescence colors from a novel source are developed.

公开(公告)号：US11963520B2

公开(公告)日：2024-04-23

申请号：US16070769

申请日：2017-01-18

Applicant: Celgene Corporation

Inventor： Rajesh Chopra ,  Anke Klippel

IPC: A01K67/027 ,  A01K67/0278 ,  A61K39/00 ,  G01N33/574

CPC classification number: A01K67/0278 ,  A61K39/001102 ,  G01N33/57484 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0331

Abstract: Provided are transgenic mice whose genome comprises a nucleic acid sequence encoding human cereblon (CRBN) or a fragment thereof, wherein endogenous mouse CRBN is not expressed in the transgenic mice. Also provided are cells, cell lines, tissues, and organs derivable from the transgenic mice, and methods for producing and using such mice.

公开(公告)号：US20240114883A1

公开(公告)日：2024-04-11

申请号：US18233507

申请日：2023-08-14

Applicant: inGenious Targeting Laboratories

Inventor： Wei Weng

IPC: A01K67/027 ,  C07K14/725

CPC classification number: A01K67/0278 ,  A01K67/0276 ,  C07K14/7051 ,  A01K2207/12 ,  A01K2207/15 ,  A01K2217/052 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/0331

Abstract: The invention provides a genetically modified non-human animal that comprises in its genome foreign γ and δ T cell receptor variable gene coding fragments, as well as its tissues, embryos, and cells. Also provided are constructs and methods for making said genetically modified non-human animal. Human T cell receptor (TCR) cloning and repertoire analysis are also included. Applications for using said animal in infectious diseases are also provided.

公开(公告)号：US11938191B2

公开(公告)日：2024-03-26

申请号：US16864613

申请日：2020-05-01

Applicant: Genevant Sciences GmbH

Inventor： Sean D. Monahan ,  Michael S. Declue ,  Pierrot Harvie ,  Russell N. Johnson ,  Amber E. Paschal ,  Mary G. Prieve ,  Debashish Roy ,  Charbel Diab ,  Michael E. Houston, Jr. ,  Anna Galperin ,  Maher Qabar

IPC: A61K47/64 ,  A01K67/027 ,  A61K38/08 ,  A61K38/44 ,  A61K47/54 ,  A61K47/58 ,  A61K48/00 ,  C08F293/00 ,  C12N15/113 ,  C12N15/87

CPC classification number: A61K47/6455 ,  A01K67/027 ,  A61K38/08 ,  A61K38/44 ,  A61K47/549 ,  A61K47/58 ,  A61K48/0041 ,  C08F293/005 ,  C12N15/113 ,  C12N15/87 ,  A01K2207/05 ,  C12N2310/14 ,  C12N2310/351 ,  C12N2320/32 ,  C12Y113/12007

Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.